共查询到16条相似文献,搜索用时 475 毫秒
1.
浅谈“me-too”药在新药研究中的地位 总被引:2,自引:2,他引:2
探索“me-too”药的研究规律,推动新药研究工作的开展;通过文献检索、分析、比较、归纳、综合,阐述“me-too”药的定义、特点、研究方法及典型事例,总结了国内外“me-too”药研究成功的经验。“me-too”药在新药研究中广泛应用。应用生物电子等排体替换、前药设计及手性药物研究等制得了大量“me-too”药物。“me-too”药是以已知药物为先导化合物,经结构修饰、结构改造而得到的新化学实体,比全新结构药物的创制研究难度低、风险小、成功率高,是新药研究的一条重要途径,也是由仿制向创制转轨的捷径。 相似文献
2.
3.
4.
随着新药研发过程的日益复杂,如何合理配置医药资源、降低研发费用、避免新药研发的风险成为世界政府和医药企业共同面对的难题。药物经济学作为一门新兴学科,其目的就是用最小的成本来获得最大的效益,在药品定价、新药研发中发挥着重要作用。本文主要研究药物经济学在新药研发中的作用,以分析与药物经济学的关系入手,进而阐述国内外医药企业在新药研发中药物经济学的应用现状,最后提出措施来推动我国医药企业在新药研发中对药物经济学的应用。 相似文献
5.
6.
《中国印刷物资商情》2011,(2):78-79
欧洲科学家利用激光驱动电子运动绘制原子全息图由荷兰、德国和法国等多国科研人员组成的研究团队,通过激光驱动电子运动绘制了原子全息图。在实验中,研究人员向一个原子或分子发射一束致密的红外激光,使原子或分子电离释放出电子,激光场驱动自由电子在离子周围做往复振荡运动,如果电子与离子相撞,就能在极短时间内发出辐射能量。 相似文献
7.
8.
9.
"通过为紧急临床需求揭示更好的生物靶标、开发新的给药方式和治疗方法等手段,化学家可帮助人类实现药物研发现代化."《化学,为了更健康的生活》白皮书提出,化学科学将拓展新药物来源,提高新药成功率,降低成本.
化学介入提高新药成功率
白皮书强调,一种在发展过程各个阶段都有化学介入的更合理的新药研发方法正在出现,即首先确定一个代表疾病途径或病原体代谢临界点的生物靶标,然后设计和合成能与靶标有效结合的化合物.确定靶标的目的是将特定基因及其生物产物与疾病联系起来.化学家将寻找新的和改进的生物靶标,以提高药物研发方案的成功率,并可提供更有效和更有针对性的药物.据悉,新型探针化合物和表型分析将有助于新靶标确定. 相似文献
10.
刘晓琳 《中国医药技术经济与管理》2010,(4):80-82
近年来,由于自动化技术特别是机器人的应用,在新药研究中出现了高通量筛选技术,该技术将化学、现代生物学、计算机以及自动化仪器等先进技术,有机组合成一个高程序、高自动化的新模式,从而创造了发现新药的新程序。由于该技术具有快速、高效的优点,已被认为是发现创新药物的重要技术手段之一, 相似文献
11.
本文从美国医药科技创新技术体系、法规体系和投融资体系等不同侧面,分析了美国创新药物的研发模式和成功经验,并提出了如何建设我国医药创新体系和提升我国医药科技自主创新能力的观点和建议,力求对提高我国新药创制能力有所裨益。 相似文献
12.
Developing countries have tried a variety of policies concerning new technology as a source of agricultural growth; there is still much debate on which is the most efficient. More study of private methods of technology transfer is needed. This article presents some preliminary statistical tests of the relationships among seed imports, private research, public research and yield. Seed imports and private research are found to be important potential sources of improved technology. Countries which restrict imports and activities by multinational seed companies may impose costs on their farmers and consumers in terms of foregone productivity. 相似文献
13.
《Food Policy》2019
The historical justifications typically given for the prohibition against deception in economic experiments are less relevant for today’s experiments that are often conducted in non-lab settings with non-student subjects. I describe a variety of research questions that might be most adequately answered with some form of deception, and call for a more nuanced view of the issue that requires a consideration of the importance of the research question relative to the potential costs of deception. For example, in the case of new food products that have not yet been developed, does the sin of hypothetical bias outweigh the sin of deceiving subjects in a non-hypothetical experiment? It is important for journals or professions, which ban the use of deception, to actually define what practices fall under the ban. 相似文献
14.
Janez Prašnikar Author Vitae Tina Škerlj Author Vitae 《Industrial Marketing Management》2006,35(6):690-702
Generic pharmaceutical companies tend to improve their market position by being first in the market when a patent on an original product elapses. The time-to-market of new products is an important source of their comparative advantages. In our study we investigate the organizational and managerial factors lying behind time-to-market in four generic pharmaceutical companies in Central and Eastern Europe. Our research also supports some results found in other studies on the lead-time of new product development. However, we find some factors specific to generic pharmaceutical companies. Our findings are incorporated into a diagnostic model of new product development in generic pharmaceutical companies, which is an important practical result of our research. 相似文献
15.
目的 为有效利用、整合现有资源,提升制药企业新药研究与开发能力提供参考,方法探讨虚拟研究与开发组织的理论及特点,结合新药研究与开发的特点,对我国应用虚拟研究与开发组织模式提升新药研发效率相关问题进行分析论证结果及结论虚拟研究与开发组织是一种适合我国制药企业新药研究与开发工作的新思路,制药企业可以选择三种模式进行虚拟研究与开发的实践政府可以通过建立合作研究中心推动虚拟研究与开发工作. 相似文献
16.
Although the resource‐based view of the firm has been written about extensively, the process by which firm assets are accumulated has not been explored in detail. That is, we know little about the micro‐level mechanisms by which assets are built, nor do we have sufficient empirical evidence why some assets are more difficult to imitate, trade, or substitute. In this exploratory paper, we attempt to provide a better understanding of asset accumulation via an empirical research program in pharmaceutical drug discovery. Using a combination of field research, discovery data from nine pharmaceutical firms, and data on 218 alliances involving new technologies for experimentation and testing, three causes affecting asset accumulation are identified and described. First, the difficulty of imitating a particular asset is affected by interdependencies with other assets. Second, trading of assets can be impeded by structural inertia in the core of a firm that is adopting the technology asset. And third, fully specifying all factors affecting imitation and trading ex ante is very difficult, if not nearly impossible, under conditions of rapid technological change. We propose that the complex interactions of these causes can give rise to imperfections in factor markets. Finally, implications for further research are discussed as well. Copyright © 2002 John Wiley & Sons, Ltd. 相似文献